deutsch
english
francais
italiano
espanol
Photo
KEYCODE BAYER 623
Felicitas Rohrer (left) during the BAYER stockholders’ meeting on 27th May in Cologne

Press Release
December 15, 2015

Germany Sees First Contraceptives Lawsuit against BAYER

Increased Thrombosis Risk through Contraceptive Pills / Coalition demands ban of Yaz, Yasminelle and Yasmin

On December 17 the regional court in Waldshut (Germany) will open civil proceedings against the pharmaceutical company BAYER because of the increased risks associated with newer contraceptive pills. The claimant is Felicitas Rohrer who suffered a severe pulmonary embolism after taking Yasminelle and only survived because of fortunate circumstances.

Felicitas Rohrer comments: “I am glad that at last proceedings have begun in Germany. There are so many countries where lawsuits are pending against BAYER for contraceptive pills containing drospirenone, and large sums have been paid for compensation. A court decision is overdue.” Rohrer claims € 200,000 damages for pain and suffering. Her lawyer also represents eight other claimants.

Following invitations from the Coalition against BAYER dangers, Ms Rohrer visited BAYER’s stockholders’ meetings several times. BAYER’s board, however, agreed neither to her offer for talks nor to her demand to ban the products.

Philipp Mimkes from the board of the Coalition also demands a ban: “The purpose of contraceptives is to prevent pregnancy and older drugs do that just as reliably as new ones. Most of the injuries caused by Yasmin, Yaz and Yasminelle could be avoided. We hope that the trial will at last lead to such a ban.”

Yaz/Yasmin is heavily advertised, especially towards girls and young women, by promising weight reduction and acne relief. However, BAYER does not draw any attention to the more pronounced risk profile associated with products containing the hormone drospirenone.

Surveys have shown that for pills containing drospirenone the risk of having an embolism or thrombosis is two to three times as high as it is for second-generation pills. In France the national health insurance no longer pays the costs for pills containing drospirenone, and the number of lethal thromboses in young women has fallen sharply. Health authorities in the United Kingdom, the Benelux countries, Denmark and Norway have given out warnings about the increased risks of taking the pills.

In 2014 BAYER’s turnover from the product family amounted to 768 million euros. BAYER has already paid damages of 1.9 billion dollars to drospirenone victims in the United States.

for more information see our campaign site

Bayer sued over controversial contraceptive pill Yasminelle

German pharmaceutical giant Bayer is due in court over claims that a birth control pill from its Yasmin range caused a woman to have a double pulmonary embolism. The firm has paid out billions in similar cases in the US.

On Thursday, a court case against German pharmaceutical giant Bayer will open in the southern German town of Waldshut-Tiengen. The law suit was first filed in May 2011 by German native Felicitas Rohrer. The former veterinary student is suing Bayer for 200,000 euros ($220,000).
The 31-year-old claims she suffered a double pulmonary embolism as a result of taking Bayer's Yasminelle contraceptive pill, which uses the hormone drospirenone. An embolism is caused by a blot clot obstructing the circulatory system.

'No existing condition'
In 2009, Rohrer, who was 25 at the time, suddenly collapsed and her heart stopped beating for 20 minutes. In emergency open-heart surgery, doctors found huge blood clots blocking the main artery to her lung.
"I didn't have a bleeding disorder, any pre-existing conditions, or any cases of illness in the family. I've never smoked, I'm not overweight and I've always exercised," Rohrer wrote on her website.
After finding no alternative explanation, doctors pointed the finger at Bayer's pill, which Rohrer had been taking for eight months when she collapsed. Since her surgery six years ago, Rohrer has had to take an anti-coagulant which reduces her chances of conceiving a child.
Rohrer's case will be the first of its kind in Germany, but in the US, such lawsuits are far from unheard of. Bayer has already had to pay out $1.9 billion in compensation in 9,000 cases of alleged side effects in the US. In 2014 alone, the company paid out 768 million euros in cases connected with with its Yasmin contraception range, which includes Yaz, Yasmin and Yasminelle.

Studies find increased risk
According to several recent studies, birth control pills containing drospirenone, such as Bayer's Yasmin range or Jenapharm's Aida and Petibelle, were found to increase the risk of an embolism or thrombosis by up to three times compared to previous generations of contraceptive pill.
Researchers in a study that assessed the data of 1.6 million Danish women who took a drospirenone contraceptive pill for several years, also found that the risk of a heart attack or stroke was higher in these women than those using a non-hormonal method of contraception.
Germany's Federal Institute for Drugs and Medical Devices (BfArM) also said they received reports from 478 women in the last 15 years who suffered from thrombosis and were also taking a contraceptive pill containing drospirenone. Sixteen of the suspected cases resulted in death.

'Positive user risk profile'
Despite the studies, Bayer insists that its contraceptive pills are safe when taken correctly. In an interview, Bayer's spokesperson for women's health, Dr Michael Diehl, said that all of the company's "combined oral contraceptives, even those containing drospirenone, have a positive user risk profile, when they're taken as indicated."
Diehl also highlighted that each prescription is based on an individual assessment of risk factors and personal health. "Before a modern, low-dose combined oral contraceptive is prescribed, a doctor and patient should have a detailed conversation about personal or family risk factors, such as smoking, obesity and thrombosis in the family".

'Aesthetic' appeal
In a report released last year by one of Germany's leading public health insurers, the Techniker Krankenkasse, pharmacologist Gerd Glaeske criticized doctors and the pharmaceutical industry for the lack of information about Bayer's Yasmin range.
It is "the first pill that has a very clear marketing angle on beauty and well-being," he argued, that opened the way for claims that contraceptive pills are effective in fighting acne.
"Due to Yasmin's anti-water-retention effects, patients are less likely to gain weight," Glaeske added.

Calls for a ban
Following her surgery, Rohrer founded a self-help group that campaigns for the pharmaceutical company to withdraw birth control containing drospirenone from the shelves.
If the campaign group were successful in banning drospirenone contraception, it wouldn't be the first time that Bayer had discontinued one of their birth control products. In neighboring France last year, the firm was forced to end sales of their acne treatment Diane-35 after four thrombosis deaths were linked to the medication.
In that case, however, Bayer had only officially approved the hormone drug to be taken to treat acne, but many doctors prescribed it instead as a contraceptive pill. After a reassessment by the European Medicine Agency, the drug was put back on sale.
While Bayer begins its legal battle on home turf on Thursday, across the pond in the US, the drugs company will also face a growing number of compensation law suits from women who claim its contraceptive implant Essure caused pain and severe bleeding.